Ophthotech Corporation to Present at 30th Annual J.P. Morgan Healthcare Conference

PRINCETON, NJ and NEW YORK, NY--(Marketwire - January 03, 2012) - Ophthotech Corp. announced today that the company will participate in the 30th Annual J.P. Morgan Healthcare Conference in San Francisco. Samir Patel, M.D., co-founder, president and chief executive officer of Ophthotech, will deliver a presentation on Jan. 11, 2012, at 10:30 a.m. PST in presentation room Elizabethan C/D at the Westin St. Francis Hotel, San Francisco.

Ophthotech is focused on developing and commercializing therapies for age-related macular degeneration (AMD), an expanding, multi-billion dollar therapeutic area. The company's lead product candidate, an anti-PDGF agent (E10030), is the first therapy to demonstrate both disease modification and significant visual gain in the majority of patients with wet AMD when co-administered with an anti-VEGF agent. Wet AMD remains a major unmet need as most patients fail to gain significant vision with monotherapy using an anti-VEGF agent, the current standard of care. A highly powered 445-patient Phase 2b trial of E10030 is fully enrolled, with results expected in the first half of 2012.

About Ophthotech
Ophthotech Corp. is a privately held biopharmaceutical company based in Princeton, NJ and New York, NY focused on developing and commercializing therapies for dry and wet AMD. Ophthotech is developing a pipeline of compounds with strong scientific foundations for the treatment of AMD, with the goal of bringing them to market in an accelerated manner. For more information, please visit www.ophthotech.com.